Agamree各版本价格一览

Agamree is also known as Vamorolone and Vamorolone. The active ingredient is Vamorolone. It is mainly used to treat patients with Duchenne Muscular Dystrophy (DMD) aged 2 years and above. It is the first and only DMD drug product to be fully approved in the EU.

List of prices for each version of Agamree

Agamree is an important drug in the treatment of DMD, and its price and acquisition methods have attracted much attention.

Launch, medical insurance and specification price

Agamree has been launched in Germany, the United States, the United Kingdom and other countries. The original drug is produced by Santhera Pharmaceuticals and was launched in Germany on January 15, 2024. It is currently not listed in the Chinese market and is not included in medical insurance. The specification produced by the original Swiss factory is 100mL/bottle, and the latest price in 2025 is approximately US$9,764 per box. Prices may change due to shipping charges, duties, or exchange rate fluctuations.

Legal purchase channels and requirements

For overseas purchases, a doctor’s prescription and patient identity certificate are required. Agamree can also be purchased on some online platforms, but the qualifications of the platform and the legality of the drug must be confirmed. During transportation, it is necessary to ensure that drugs are kept in the cold chain throughout the entire process to avoid high temperatures or freezing. When purchasing Agamree online, it is recommended to choose a platform that provides full logistics tracking services, and check whether the drug batch number is consistent with the original manufacturer information.

After purchasing Agamree, you can identify the authenticity by checking the packaging integrity, drug batch number and anti-counterfeiting mark. If there is delamination, discoloration or odor in the solution, stop using it immediately and contact the supplier.

Potential side effects of Agamree

The use of Agamree may be accompanied by certain adverse reactions. Patients need to understand the relevant symptoms and countermeasures. The following are common side effects and treatment methods.

Cushingoid changes and endocrine problems

Long-term use of Agamree may lead to Cushing's syndrome-like symptoms such as facial roundness, fragile skin, and weight gain. If symptoms are obvious, you can contact your doctor to adjust the dosage or combine it with other treatment options. Regularly monitor blood sugar, bone density and adrenal function, and supplement calcium or vitamin D if necessary.

Gastrointestinal Reactions and Infection Risks

Gastrointestinal discomforts such as vomiting and diarrhea can be relieved by eating small amounts more frequently and avoiding irritating foods. In severe cases, antiemetic or antidiarrheal drugs can be used. The risk of infection increases due to immunosuppression. Patients need to avoid contact with sources of infectious diseases and seek medical attention immediately when symptoms such as fever or cough occur.

If blurred vision or increased intraocular pressure occurs during medication, treatment should be suspended and an eye examination should be performed to prevent further aggravation of glaucoma or cataracts.

Daily care for Duchenne muscular dystrophy

Scientific daily care can improve the quality of life of DMD patients and delay the progression of the disease. The following are key care recommendations.

Exercise and rehabilitation training

Carry out low-intensity rehabilitation exercises under the guidance of a doctor, such as water activities, joint stretching, etc., to maintain muscle function. Avoid excessive fatigue or strenuous exercise to prevent muscle damage. Use orthotics or a wheelchair to assist mobility and reduce the risk of falls.

Nutritional and psychological support

The diet needs to be rich in protein, vitamins and minerals, and caloric intake should be controlled to avoid obesity. Patients with dysphagia may choose soft foods or nutritional supplements. In terms of psychology, family members should provide emotional support and seek professional psychological counseling when necessary to help patients cope with anxiety or depression.

Patients need to regularly review creatine kinase levels, cardiopulmonary function and joint mobility, conduct bone density testing every 6 months, undergo ophthalmology and endocrine system evaluations every year, and adjust treatment plans in a timely manner.